Payment overview · 2025
General Payments
$172.52
8 reported records · 5 companies
Healthcare provider profile · identity verified
Mark Duca, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PITTSBURGH, PA · NPI 1023081445
Verified facts
What the public records show
CMS Open Payments records show Mark Duca, MD received $172.52 in general payments during 2025 across 8 reported records.
GlaxoSmithKline, LLC. accounted for 46.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Trelegy Ellipta.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $79.88 | 46.3% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $31.03 | 18.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.81 | 15.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.07 | 12.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.73 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $172.52 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $79.88 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $45.76 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 237 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
237 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
237 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 761 | 199 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 89 |
| Losartan Potassium | Losartan Potassium | 314 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 57 |
| Eliquis | Apixaban | 237 | 30 |
| Sertraline Hcl | Sertraline Hcl | 218 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 217 | 69 |
| Furosemide | Furosemide | 179 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 43 |
| Omeprazole | Omeprazole | 175 | 40 |
| Simvastatin | Simvastatin | 175 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 47 |
| Lisinopril | Lisinopril | 164 | 37 |
| Tramadol Hcl | Tramadol Hcl | 148 | 19 |
| Metformin Hcl | Metformin Hcl | 145 | 35 |
| Trazodone Hcl | Trazodone Hcl | 132 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 26 |
| Potassium Chloride | Potassium Chloride | 118 | 23 |
| Ibuprofen | Ibuprofen | 113 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 16 |
| Metformin Hcl Er | Metformin Hcl | 107 | 35 |
| Jardiance | Empagliflozin | 106 | 15 |
| Gabapentin | Gabapentin | 103 | 21 |
| Allopurinol | Allopurinol | 101 | 23 |
| Alendronate Sodium | Alendronate Sodium | 97 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 28 |
| Ozempic | Semaglutide | 86 | 13 |
| Carvedilol | Carvedilol | 84 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 21 |
| Clonazepam | Clonazepam | 83 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 79 | 16 |
| Azithromycin | Azithromycin | 78 | 73 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | suppressed |
| Alprazolam | Alprazolam | 71 | 15 |
| Xarelto | Rivaroxaban | 69 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | suppressed |
| Januvia | Sitagliptin Phosphate | 65 | suppressed |
| Lorazepam | Lorazepam | 65 | 14 |
| Meloxicam | Meloxicam | 62 | 14 |
| Mirtazapine | Mirtazapine | 62 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 62 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 38 |
| Synthroid | Levothyroxine Sodium | 57 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Famotidine | Famotidine | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 46 | 16 |
| Methylprednisolone | Methylprednisolone | 46 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 18 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 13 |
| Finasteride | Finasteride | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Atovaquone-Proguanil Hcl | Atovaquone/Proguanil Hcl | 29 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Perphenazine | Perphenazine | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 16 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 22 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Gatifloxacin | Gatifloxacin | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Prednisone | Prednisone | 19 | 14 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Aranesp | Darbepoetin Alfa In Polysorbat | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Klor-Con | Potassium Chloride | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Enbrel | Etanercept | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $172.52 · 8 records | GlaxoSmithKline, LLC. | Cologuard Collection Kit, ELIQUIS, MOUNJARO, NURTEC ODT, TRELEGY ELLIPTA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error